1. What is FFR Intas?
FFR (Fractional Flow Reserve) Intas is a diagnostic technology developed by Intas Pharmaceuticals, primarily used in interventional cardiology to assess the severity of coronary artery blockages. During coronary angiography—a procedure where a catheter is inserted into the coronary arteries to observe any narrowing—FFR Intas measures the pressure difference across a narrowed artery.
The FFR value helps doctors understand how much a coronary blockage is restricting blood flow to the heart. The pressure is measured before (proximal) and after (distal) the narrowed area, with the ratio between the two pressure points providing the FFR value. This value is key to making treatment decisions regarding coronary blockages.
2. Why is FFR Intas Important?
Traditionally, assessing coronary artery blockages relied heavily on visual estimations from imaging technologies like angiograms. However, these can sometimes overestimate or underestimate the severity of a blockage. FFR Intas offers a more accurate method by providing real-time data that reflects the functional impact of a blockage on blood flow.
With an FFR value:
- A reading close to 1 suggests the artery is not significantly blocked, meaning no immediate intervention may be necessary.
- A reading below 0.80 suggests the blockage is severe enough to warrant procedures such as angioplasty or stenting.
This allows cardiologists to make more informed decisions, ensuring that interventions are only carried out when necessary, avoiding overtreatment.
How FFR Intas Works
1. The Procedure
FFR Intas is typically performed during coronary angiography. Once the catheter is in place, a pressure wire is passed through the narrowed segment of the artery to measure pressure before and after the narrowing.
2. Key Steps:
- Coronary Angiography: This involves threading a catheter into the coronary arteries.
- Pressure Measurement: The FFR Intas system measures the pressure before and after the narrowed artery.
- Calculation of FFR Value: The system calculates the FFR value as the ratio of distal to proximal pressure.
- Decision Making: Based on the FFR value, cardiologists determine if revascularization is required. A value above 0.80 generally means the blockage is not critical, while a value below 0.80 signals a need for intervention.
3. Benefits for Patients
FFR Intas significantly improves patient outcomes by ensuring that only patients who truly need an intervention receive it. It avoids unnecessary stenting or angioplasty, reducing potential risks and complications associated with such procedures.
Logging into FFR Intas
For cardiologists and healthcare professionals using FFR Intas, accessing the system is simple and secure. Here’s a quick guide on how to log in:
1. Steps to Log In:
- Visit the official FFR Intas website at FFR Intas Login.
- Enter your username and password.
- Click the “Log In” button to access your account.
For added security, you may be required to input a one-time code sent to your registered mobile phone number. In case of forgotten login details, there are options to recover your username or reset your password.
About Intas Pharmaceuticals
1. Company Background
Intas Pharmaceuticals, the parent company behind FFR Intas, has established itself as a key player in the global pharmaceutical industry. Founded in 1977 by Hasmukh Chudgar, Intas has grown exponentially, with a strong focus on drug development, manufacturing, and marketing. The company was incorporated in 1985, and over the years, it has become a prominent name in addressing unmet medical needs through innovative pharmaceutical solutions.
2. Key Milestones:
- 2013: ChrysCapital bought a 16.14% stake in Intas Pharmaceuticals, signaling investor confidence in the company’s growth.
- 2017: Temasek Holdings, a Singapore-based sovereign wealth fund, acquired 10.13% of the company’s shares.
- 2020: ChrysCapital repurchased Capital International’s stake, solidifying its position in the company.
Today, the Chudgar family controls 83.85% of the company’s shares, while Temasek Holdings and ChrysCapital hold 10.13% and 6.02%, respectively.
3. Global Reach and Manufacturing Capabilities
As of 2021, Intas operates 19 manufacturing facilities worldwide, including:
- 13 facilities in India
- 5 in the UK
- 1 in Mexico
In addition, the company has recently opened a new manufacturing facility near Ahmedabad, capable of producing over 1 billion solid dosage forms and 5 million injectables annually. This expansion has positioned Intas as a global leader in pharmaceutical manufacturing.
Key Contributions of Intas Pharmaceuticals
1. Intas’ Commitment to Quality
Intas Pharmaceuticals is known for its rigorous quality standards, which are reflected in all its products and services. The company is committed to enhancing healthcare by developing drugs that meet the highest standards of safety and efficacy.
2. Accord Healthcare
Intas’ global presence is strengthened by its subsidiary, Accord Healthcare, which operates in international markets. Through organic growth and strategic acquisitions, Intas has expanded its product portfolio, particularly in North America and Europe, where it has established itself as a trusted name in the industry.
3. Focus on Biosimilars and New Chemical Entities
Intas has been at the forefront of developing biosimilars and new chemical entities, which are seen as the future of healthcare. By focusing on these complex and hard-to-approve drugs, the company is contributing to the global advancement of medical treatments, especially in the areas of oncology and autoimmune diseases.
4. Biologics Unit
In 2006, Intas Pharmaceuticals launched Intas Biopharmaceuticals, an independent biotechnology division focused on developing biosimilar products. This unit merged with the parent company in 2012–2013. One of its significant achievements was becoming the first Indian company to receive EU-GMP (Good Manufacturing Practices) certification for its biosimilar products. The company’s first biosimilar product, Filgrastim, was launched in Europe in 2015, marking a significant milestone in the treatment of immune system disorders like neutropenia.
Conclusion
FFR Intas and Intas Pharmaceuticals are playing crucial roles in modern healthcare, offering innovative solutions that enhance patient care and treatment. FFR Intas, as a diagnostic tool, has transformed the way cardiologists assess and treat coronary artery disease, ensuring that interventions are made only when absolutely necessary.
Meanwhile, Intas Pharmaceuticals continues to break new ground in drug development, manufacturing, and marketing, with a particular focus on biosimilars and new chemical entities. Through its global operations and commitment to quality, Intas is shaping the future of healthcare, one innovation at a time.
